Want to see SRPT full AI Analyst Report?

Sarepta Therapeutics (SRPT) Stock Forecast & Price Target

4,072 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SRPT Analyst Ratings

Hold

3 Buy

10 Hold

4 Sell

Based on 17 analysts giving stock ratings to

Sarepta

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SRPT Stock 12 Month Forecast

Average Price Target

$21.53

▲(13.81% Upside)

Based on 17 Wall Street analysts offering 12 month price targets for Sarepta Therapeutics in the last 3 months. The average price target is $21.53 with a high forecast of $38.00 and a low forecast of $5.00. The average price target represents a 13.81% change from the last price of $18.92.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","39":"$39","12.75":"$12.75","21.5":"$21.5","30.25":"$30.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$38.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.533333333333335,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$21.53</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,12.75,21.5,30.25,39],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.57,19.141538461538463,20.713076923076922,22.284615384615385,23.856153846153845,25.427692307692308,26.99923076923077,28.57076923076923,30.142307692307693,31.713846153846156,33.285384615384615,34.85692307692308,36.42846153846154,{"y":38,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.57,17.874871794871794,18.17974358974359,18.484615384615385,18.789487179487182,19.094358974358975,19.39923076923077,19.704102564102566,20.00897435897436,20.313846153846157,20.61871794871795,20.923589743589744,21.22846153846154,{"y":21.533333333333335,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.57,16.603076923076923,15.636153846153846,14.669230769230769,13.702307692307691,12.735384615384614,11.768461538461539,10.801538461538462,9.834615384615384,8.867692307692307,7.90076923076923,6.933846153846153,5.966923076923077,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19.32,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 15</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":24.01,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":19.72,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":21.52,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 14</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":20.72,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.32,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 17</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.13,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.49,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.61,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.2,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":14.86,"date":1785542400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":21.33,"date":1788220800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":17.57,"date":1790812800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$38.00

Average Price Target$21.53

Lowest Price Target$5.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ritu Baral

TD Cowen

$17

Hold

-10.15%

Downside

Reiterated

10/21/26

Sarepta Therapeutics (SRPT) Receives a Rating Update from a Top Analyst

Mitchell Kapoor

H.C. Wainwright

Sell

-73.57%

Downside

Reiterated

10/19/26

Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (NASDAQ: JANX), Sarepta Therapeutics (NASDAQ: SRPT) and Adagene (NASDAQ: ADAG)

Biren Amin

Piper Sandler

$20

Hold

5.71%

Upside

Reiterated

10/19/26

Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (NASDAQ: DFTX), Sarepta Therapeutics (NASDAQ: SRPT) and BioNTech SE (NASDAQ: BNTX)

Yun Zhong

Wedbush

$35

Buy

84.99%

Upside

Reiterated

10/16/26

Sarepta Therapeutics: Buy Rating Reiterated on Expanding RNA Pipeline; Price Target Maintained at $35

Unknown Analyst

Leerink Partners

Not Ranked

Leerink Partners

$20

Hold

5.71%

Upside

Reiterated

10/15/26

Leerink Partners Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)

Brian Abrahams

RBC Capital

$17

Hold

-10.15%

Downside

Reiterated

10/09/26

Sarepta price target lowered to $17 from $19 at RBC CapitalSarepta price target lowered to $17 from $19 at RBC Capital

Tazeen Ahmad

Bank of America Securities

$18

Sell

-4.86%

Downside

Reiterated

10/09/26

Bank of America Securities Reaffirms Their Sell Rating on Sarepta Therapeutics (SRPT)

Yanan Zhu

Wells Fargo

$38

Buy

100.85%

Upside

Reiterated

10/02/26

Wells Fargo Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)

Anupam Rama

J.P. Morgan

$23→$20

Hold

5.71%

Upside

Assigned

09/30/26

Sarepta price target lowered to $20 from $23 at JPMorganSarepta price target lowered to $20 from $23 at JPMorgan

Gil Blum

Needham

―

Sell

―

Reiterated

09/28/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT), BioNTech SE (NASDAQ: BNTX) and AgomAb Therapeutics NV ADR (NASDAQ: AGMB)

Lachlan Hanbury Brown

William Blair

―

Hold

―

Reiterated

09/28/26

Elevidys ENDURE Study Shows Partial Risk Mitigation but Persistent Safety Concerns, Supporting Hold Rating

Yigal Nochomovitz

Citi

$13

Sell

-31.29%

Downside

Reiterated

09/27/26

Sell Rating Reaffirmed on Sarepta as Regulatory Uncertainty Persists; $13 Price Target Maintained

Gavin Clark-Gartner

Evercore ISI

$19

Hold

0.42%

Upside

Reiterated

08/10/26

Evercore ISI Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)

Eliana Merle

Barclays

$20

Hold

5.71%

Upside

Reiterated

08/07/26

Barclays Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)

Michael Ulz

Morgan Stanley

$25

Hold

32.14%

Upside

Assigned

08/06/26

Morgan Stanley Keeps Their Hold Rating on Sarepta Therapeutics (SRPT)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ritu Baral

TD Cowen

$17

Hold

-10.15%

Downside

Reiterated

10/21/26

Sarepta Therapeutics (SRPT) Receives a Rating Update from a Top Analyst

Mitchell Kapoor

H.C. Wainwright

Sell

-73.57%

Downside

Reiterated

10/19/26

Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (NASDAQ: JANX), Sarepta Therapeutics (NASDAQ: SRPT) and Adagene (NASDAQ: ADAG)

Biren Amin

Piper Sandler

$20

Hold

5.71%

Upside

Reiterated

10/19/26

Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (NASDAQ: DFTX), Sarepta Therapeutics (NASDAQ: SRPT) and BioNTech SE (NASDAQ: BNTX)

Yun Zhong

Wedbush

$35

Buy

84.99%

Upside

Reiterated

10/16/26

Sarepta Therapeutics: Buy Rating Reiterated on Expanding RNA Pipeline; Price Target Maintained at $35

Unknown Analyst

Leerink Partners

Not Ranked

Leerink Partners

$20

Hold

5.71%

Upside

Reiterated

10/15/26

Leerink Partners Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)

Brian Abrahams

RBC Capital

$17

Hold

-10.15%

Downside

Reiterated

10/09/26

Sarepta price target lowered to $17 from $19 at RBC CapitalSarepta price target lowered to $17 from $19 at RBC Capital

Tazeen Ahmad

Bank of America Securities

$18

Sell

-4.86%

Downside

Reiterated

10/09/26

Bank of America Securities Reaffirms Their Sell Rating on Sarepta Therapeutics (SRPT)

Yanan Zhu

Wells Fargo

$38

Buy

100.85%

Upside

Reiterated

10/02/26

Wells Fargo Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)

Anupam Rama

J.P. Morgan

$23→$20

Hold

5.71%

Upside

Assigned

09/30/26

Sarepta price target lowered to $20 from $23 at JPMorganSarepta price target lowered to $20 from $23 at JPMorgan

Gil Blum

Needham

―

Sell

―

Reiterated

09/28/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT), BioNTech SE (NASDAQ: BNTX) and AgomAb Therapeutics NV ADR (NASDAQ: AGMB)

Lachlan Hanbury Brown

William Blair

―

Hold

―

Reiterated

09/28/26

Elevidys ENDURE Study Shows Partial Risk Mitigation but Persistent Safety Concerns, Supporting Hold Rating

Yigal Nochomovitz

Citi

$13

Sell

-31.29%

Downside

Reiterated

09/27/26

Sell Rating Reaffirmed on Sarepta as Regulatory Uncertainty Persists; $13 Price Target Maintained

Gavin Clark-Gartner

Evercore ISI

$19

Hold

0.42%

Upside

Reiterated

08/10/26

Evercore ISI Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)

Eliana Merle

Barclays

$20

Hold

5.71%

Upside

Reiterated

08/07/26

Barclays Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)

Michael Ulz

Morgan Stanley

$25

Hold

32.14%

Upside

Assigned

08/06/26

Morgan Stanley Keeps Their Hold Rating on Sarepta Therapeutics (SRPT)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AMRXAmneal Pharmaceuticals

DNTHDianthus Therapeutics

ONCBeOne Medicines

IRLAIRulya Therapeutics

IDYAIDEAYA Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sarepta Therapeutics

3 Months

Mitchell KapoorH.C. Wainwright

Success Rate

14/18 ratings generated profit

Average Return

+10.22%

Copying Mitchell Kapoor's trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +10.22% per trade.

1 Year

Mitchell KapoorH.C. Wainwright

Success Rate

13/18 ratings generated profit

Average Return

+16.16%

Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 72.22% of your transactions generating a profit, with an average return of +16.16% per trade.

2 Years

Mitchell KapoorH.C. Wainwright

Success Rate

12/18 ratings generated profit

Average Return

+14.03%

Copying Mitchell Kapoor's trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +14.03% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SRPT Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SRPT has received 7 Buy Ratings, 16 Hold Ratings, and 9 Sell Ratings. SRPT average Analyst price target in the past 3 months is 21.53.

Each month's total comprises the sum of three months' worth of ratings.

SRPT Financial Forecast

SRPT Earnings Forecast

Next quarter’s earnings estimate for SRPT is $0.07 with a range of -$0.50 to $0.78. The previous quarter’s EPS was -$0.05. SRPT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year SRPT has Performed in-line its overall industry.

SRPT Sales Forecast

Next quarter’s sales forecast for SRPT is $352.20M with a range of $322.44M to $381.50M. The previous quarter’s sales results were $401.25M. SRPT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year SRPT has Performed in-line its overall industry.

SRPT Stock Forecast FAQ

What is SRPT’s average 12-month price target, according to analysts?

Based on analyst ratings, Sarepta Therapeutics’s 12-month average price target is 21.53.

What is SRPT’s upside potential, based on the analysts’ average price target?

Sarepta Therapeutics has 13.81% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is SRPT a Buy, Sell or Hold?

Sarepta Therapeutics has a consensus rating of Hold which is based on 3 buy ratings, 10 hold ratings and 4 sell ratings.

What is Sarepta Therapeutics’s price target?

The average price target for Sarepta Therapeutics is 21.53. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $38.00 ,the lowest forecast is $5.00. The average price target represents 13.81% Increase from the current price of $18.92.

What do analysts say about Sarepta Therapeutics?

Sarepta Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 17 Wall Streets Analysts.

How can I buy shares of SRPT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Sarepta Therapeutics (SRPT) Stock Forecast & Price Target

SRPT Analyst Ratings

SRPT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Sarepta Therapeutics

SRPT Analyst Recommendation Trends

SRPT Financial Forecast

SRPT Earnings Forecast

SRPT Sales Forecast

SRPT Stock Forecast FAQ

Detailed List of Analyst Forecasts